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1202Objective: Under Food and Drug Administration investigational device exemption, the Prospective Random-
ized On-X Anticoagulation Clinical Trial (PROACT) has been testing the safety of less aggressive anticoagu-
lation than recommended by the American College of Cardiology/American Heart Association guidelines
after implantation of an approved bileaflet mechanical valve.
Methods: In this first limb of the PROACT, patients with elevated risk factors for thromboembolismwere random-
ized at 33 US centers to receive lower dose warfarin (test international normalized ratio [INR], 1.5-2.0) or continue
standardwarfarin (control INR, 2.0-3.0), 3months aftermechanical aortic valve replacement. The INRwas adjusted
by home monitoring; all patients received 81 mg aspirin daily. Adverse events were independently adjudicated.
Results: A total of 375 aortic valve replacement patients were randomized into control (n ¼ 190) and test
(n ¼ 185) groups from September 2006 to December 2009. The mean age  standard deviation was 55.2 
12.5 years; 79% were men; and 93% were in sinus rhythm preoperatively. Calcific degeneration was present
in 67%; active endocarditis was excluded. Concomitant procedures included coronary artery bypass grafting
(27%), aortic aneurysm repair (14%), and other (25%). The follow-up duration averaged 3.82 years (755.7
patient-years [pt-yrs] for control; 675.2 pt-yrs for test). The mean INR was 2.50  0.63 for the control and
1.89  0.49 for the test groups (P<.0001). The test group experienced significantly lower major (1.48% vs
3.26%/pt-yr; P ¼ .047) and minor (1.32% vs 3.41%/pt-yr; P ¼ .021) bleeding rates. The incidence of stroke,
transient ischemic attack, total neurologic events, and all-cause mortality were similar between the 2 groups.
Conclusions: INR can be safely maintained between 1.5 and 2.0 after aortic valve replacement with this
approved bileaflet mechanical prosthesis. With low-dose aspirin, this resulted in a significantly lower risk of
bleeding, without a significant increase in thromboembolism. (J Thorac Cardiovasc Surg 2014;147:1202-11)Supplemental material is available online.
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Abbreviations and Acronyms
AVR ¼ aortic valve replacement
INR ¼ international normalized ratio
PROACT ¼ Prospective Randomized On-X
Anticoagulation Clinical Trial
pt-yrs ¼ patient-years
TE ¼ thromboembolism
TIA ¼ transient ischemic attack
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Dstructurally fail at 10 to 15 years after implantation.1 The
present mechanical valves also fall short of this ideal, given
the inconvenience of warfarin and the annual risk of
bleeding of about 1% to 2%.2 The negative aspects com-
mon to both valve types have included perivalvular leak,
prosthetic valve endocarditis, pannus, and thromboemboli.
These can result in reoperation, stroke, or death; however,
they are rare and appear to affect both valve categories
equivalently.3 Thus, the choice between valve types narrows
to one of avoidance of the risk, pain, and costs of reopera-
tion for valve obsolescence versus avoidance of the lifetime
composite risk of bleeding and thromboembolism (TE) and
the nuisance of ongoing anticoagulation management.
The On-X valve is a Food and Drug Administration
(FDA)–approved, bileaflet mechanical valve designed to
function with less anticoagulation, or in some cases, anti-
platelet therapy only. Conducted under an FDA investiga-
tional device exemption, the Prospective Randomized
On-X Anticoagulation Clinical Trial (PROACT) was de-
signed to test whether it is safe and effective to treat patients
with less aggressive anticoagulant therapy than currently
recommend by the American College of Cardiology/Amer-
ican Heart Association4 or American College of Clinical
Pharmacy5 guidelines after implantation of an approved bi-
leaflet mechanical valve prosthesis. PROACT is composed
of 3 separate cohorts. The first cohort to complete enroll-
ment was used to compare standard anticoagulant therapy
versus international normalized ratio (INR) goal of 1.5 to
2.0 in high-risk patients requiring aortic valve replacement
(AVR). The second will be used to compare current antico-
agulant therapy versus aspirin and/or clopidogrel only in
selected lower risk patients requiring AVR. The third will
be to compare standard anticoagulation therapy versus
INR goal of 2 to 2.5 in patients requiring mitral valve
replacement. The subject of the present report was the first
cohort of patients.
METHODS
Study Design and Patient Selection
The high-risk AVR limb of the PROACT study (ClinicalTrials.gov no.
NCT00281525) is a prospective, randomized, unblinded, controlled trial
comparing the outcomes after AVR with the On-X valve. It is a multicenter
study consisting of 33 centers in North America (see Appendix E1). A total
of 425 patients were recruited in the first cohort for AVR in subjects at highThe Journal of Thoracic and Carrisk of TE. Enrollment began after institutional review board approval at
each enrolling site in June 2006 and was closed for the high-risk AVR
group in October 2009. Interim follow-up data through March 1, 2013
were available for the present report. The primary endpoints were the rates
of TE, thrombosis and bleeding, and all-cause mortality, as defined by the
Society of Thoracic Surgeons/American Association for Thoracic Surgery
guidelines for valve studies.6 Noninferiority between the 2 groups was
determined using the composite TE, thrombosis and bleeding rate, and a
noninferiority margin of 1.5% (absolute). The sample size estimation
was determined using a 1-sided proportion test with a type 1 error of
0.05 and power of 80% to test the noninferiority hypothesis.
Patient Inclusion Criteria
The patient inclusion criteria were as follows:
1. Patients with a clinical indication for isolated AVR
2. Patients with the following conditions, which place a patient in the
‘‘high-risk’’ group: chronic atrial fibrillation, left ventricular ejection
fraction<30%, enlarged left atrium>50 mm in diameter, spontaneous
echocardiographic contrasts in the left atrium, vascular pathologic fea-
tures, neurologic events, hypercoagulability, left or right ventricular
aneurysm, lack of a platelet response to aspirin or clopidogrel, and
women receiving estrogen replacement therapy
3. Concomitant cardiac surgery, including coronary artery bypass grafting,
mitral or tricuspid valve repair, ascending aortic replacement, maze pro-
cedure, and so forth, were allowed
4. Adult patients (age, 18 years)Patient Exclusion Criteria
The patient exclusion criteria were as follows:
1. Right-sided valve replacement
2. Double (aortic plus mitral) valve replacement
3. Patients with active endocarditis at implantation
Hypercoagulability in the AVR patients was defined by the following
blood tests done preoperatively and before the initiation of warfarin therapy:
activated protein C resistance (factor V–Leiden mutation), prothrombin
mutation, antithrombin III activity, proteinCactivity, protein S activity, factor
VIII activity, and low-density lipoprotein.Resistance to aspirin or clopidogrel
in AVR patients was defined from clinical laboratory test results: urine
11-dehydro-thromboxane B2 for aspirin and P2Y12 for clopidogrel.
Randomization to Test and Control Groups and
Crossover Between Groups
All patients received routine warfarin with a target INR of 2.0 to 3.0,
plus 81 mg aspirin daily for the first 3 postoperative months. At 90 days
postoperatively, 1:1 randomization was performed using a standard
randomization Mersenne Twister algorithm through an on-line randomiza-
tion module.
Test group: for the first 3 postoperative months, warfarin at an INR
target of 2.0 to 3.0 with aspirin 81 mg/d was used. After 3 months,
the warfarin dosewas reduced to an INR target of 1.5 to 2.0, with 81
mg/d of enteric-coated aspirin.
Control group: Postoperatively, warfarin at an INR target of 2.0 to 3.0
with 81 mg/d aspirin was used throughout the study period.
The trial design decision to delay randomization until postoperative day
90 was determined by the belief that randomization to a less aggressive an-
ticoagulation regimen would be safer if conducted after an initial period of
3 months of conventional anticoagulation, during which the fabric sewing
cuff of the mechanical valve prosthesis would have become
endothelialized.diovascular Surgery c Volume 147, Number 4 1203
Acquired Cardiovascular Disease Puskas et al
A
C
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over to standard anticoagulation therapy (INR, 2.0-3.0 plus 81 mg/d
aspirin), although such patients remained in the test group by intention-
to-treat. The FDA protocol did not allow crossover from the control to
the test therapy.
Primary Endpoints
The primary endpoints mandated by the FDA included major bleeding
events, minor bleeding events, total bleeding events, transient ischemic
attack (TIA), hemorrhagic stroke, nonhemorrhagic stroke, any neurologic
event, peripheral TE, any TE, valve thrombosis, TE and thrombosis, major
event (major bleeding, any TE, valve thrombosis), death (cardiac, noncar-
diac, valve-related, and all-cause).
Secondary Endpoints
The secondary endpoints included endocarditis, hemolysis, hemolytic
anemia, paravalvular leak, structural and nonstructural dysfunction, post-
operative New York Heart Association class and echocardiographic
hemodynamics.
Follow-up Schedule
The patients were followed up by in-person visits to the study sites at 3
months, 6 months, and 1 year after surgery and then annually for5 and as
much as 8 postoperative years to accrue the necessary 800 patient-years of
follow-up mandated by the FDA. During these visits, electrocardiography
or echocardiography was performed as required by the protocol and as clin-
ically indicated. All patients maintained with warfarin therapy were fol-
lowed up using weekly home INR testing through a central telephone or
online database. The follow-up period was through March 1, 2013 and
was complete in 98% of patients.
INR Management
All patients received a home INR monitor at randomization. The INR
control was maintained using weekly home testing, with warfarin dose ad-
justments made by the clinical sites to minimize INR variability and maxi-
mize the time in the INR target range. Compliance to homemonitoring was
determined by the frequency of the tests conducted monthly.
Statistical Analysis
The descriptive statistics for the numeric measures are reported as the
mean  standard deviation. Statistical tests were conducted using the 2-
sample Z test for the mean values and the chi-square (or Fisher’s exact)
test for proportions. Early adverse events were those occurring before
randomization and were calculated as percentages. Late (postrandomiza-
tion) linearized adverse event rates in %/patient-year (pt-yr) were
compared using relative risk ratios and the intent-to treat method for all
subjects who had received 1 dose of the study drug. Kaplan-Meier life
table curves were calculated from the point of randomization to the first
event and compared using the log-rank test. The analyses were performed
using Statistical Analysis Systems statistical software, version 9.2
(SAS Institute, Cary, NC).RESULTS
From June 2006 to October 2009, 425 patients were
enrolled in the AVR high-risk arm of the PROACT trial.
The Consolidated Standards of Reporting Trials (CON-
SORT) flow diagram is shown in Appendix E2. Of these
425 patients, 185 were randomized after 3 postoperative
months to the test group and 190 to the control group.
The follow-up period averaged 3.82 years through March1204 The Journal of Thoracic and Cardiovascular Sur1, 2013 (755.7 pt-yrs for the control group and 675.2 pt-
yrs for the test group). The remaining 50 patients were
removed from the trial before randomization for the
following reasons: death (n ¼ 8), adverse event exclusion
by protocol (n ¼ 10), different or no surgery performed
(n ¼ 14), voluntary withdrawal by patient or physician
(n ¼ 11), protocol criterion exclusion (n ¼ 3), explantation
(n ¼ 1), and lost to follow-up (n ¼ 3). The mean age at sur-
gery was 55.8  12.0 years (range, 22-85) for the control
group and 54.1  13.0 years (range, 20-83) for the test
group (P ¼ .187). In the control and test groups, 81% and
80% of the patients were men, respectively (P ¼ .898).
The present interim analysis was performed because a
widening divergence in the incidence of bleeding events be-
tween the 2 groups suggested that a difference was possible
and early termination might be appropriate, although this
investigational device exemption trial continues, pending
the FDA ruling.
Comparisons between the 2 groups for native valve path-
ologic features, valve lesion, preoperative New York Heart
Association classification, clinical risk factors, and
abnormal laboratory test results are listed in Table 1. No sta-
tistically significant differences were found.
The patients were considered minimally compliant if
their frequency of testing was at least twice monthly—
approximately twice as often as conventional INR moni-
toring in a clinician outpatient office. The patients were
considered fully compliant when their frequency of testing
was 3 times monthly. Ideal home monitoring would have
resulted in an average interval between the tests of 7 days. In
the present study, the average interval between tests was 9
days in both groups. More than 80% of the patients were
minimally compliant with the homemonitoring procedures,
>20% were ideally compliant, and 96% of all patients at
least attempted to conduct home testing once. Finally, 4%
of patients refused home INR monitoring altogether and
were monitored by their local physicians at clinic visits.
The mean INR was 1.89 0.50 for the test subjects (target,
1.5-2.0) and 2.50 0.64 for the control subjects (target, 2.0
to 3.0). The difference in the INR test results for the groups
was highly significant (P<.0001).
Figure 1 shows the distribution of INR measurements by
group, clearly demonstrating the lower INR levels main-
tained in the test group. The percentage of INR measure-
ments in the target range was 63.6% for the test group
and 69.8% for the control group. The test group in-range
percentage was similar to that of the control group, despite
the narrower target range. The mean and median INR were
within the target range for both groups. The percentage of
readings >3.0 or <1.5 was 17.6% in the control and
14.0% in the test group, respectively. These values were
the points at which the observed rates of bleeding or TE
events began to increase. Figure 2 displays the bleeding
and TE event rates stratified by the INR level at the timegery c April 2014
TABLE 1. Preoperative characteristics of test and control groups
Class/test
AVR high risk
P value
Test
(n ¼ 185)
Control
(n ¼ 190)
Valve pathologic findings (etiology)
Rheumatic 3 (2) 3 (2) .71
Calcific 121 (65) 130 (68) .61
Bicuspid 69 (37) 72 (38) .93
Endocarditis 4 (4) 5 (3) .81
Degenerative 31 (17) 32 (17) .89
Prosthetic valve dysfunction 8 (4) 9 (5) .79
Valve lesion .24
Stenosis 95 (52) 97 (51)
Regurgitation 46 (25) 34 (18)
Mixed 39 (21) 54 (28)
NYHA class .44
I 39 (21) 36 (19)
II 73 (39) 73 (38)
III 50 (27) 51 (27)
IV 7 (4) 16 (8)
Unknown 16 (9) 14 (7)
Clinical risk factors
Atrial fibrillation 3 (2) 11 (6) .06
Ejection fraction<30% 9 (5) 7 (4) .75
Estrogen therapy 4 (2) 2 (1) .66
Left atrial diameter>50 mm 15 (8) 22 (12) .34
Neurologic events 6 (3) 9 (5) .63
Spontaneous echocardiographic
contrasts
0 (0) 2 (1) .46
Ventricular aneurysm 1 (0.5) 1 (0.5) .46
Abnormal laboratory tests
AT-III activity 28 (15) 24 (13) .58
Factor VIII activity 1 (0.5) 1 (0.5) .46
Factor V Leiden mutation 5 (3) 3 (2) .48
Protein C activity 9 (5) 9 (5) .70
Prothrombin mutation 4 (2) 3 (2) .96
Protein S activity 3 (2) 3 (2) .68
P2Y12 inhibition 42 (23) 52 (27) .35
Urine thromboxane 84 (45) 69 (36) .09
Data presented as n (%). Incidence rates by disease etiology and comparison of test
and control groups using a chi-square test of significance (including Yates’ correction
for continuity for small sample sizes). AVR, Aortic valve replacement; NYHA, New
York Heart Association; AT-III, antithrombin III.
FIGURE 1. International normalized ratio (INR) distributions.
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The best fit curves of the data are also shown, indicating an
intersection between the bleeding and TE curves at the INR
1.5 to 2.0 range. These curves also indicated that the inci-
dence of TE increased when the INR decreased to<1.5,
suggesting 1.5 as the lower boundary of appropriate
warfarin anticoagulation in this patient population with pre-
operative risk factors for TE.
Patients experiencing serious adverse events, including
death and TE, before randomization at 3 postoperative
months were excluded from randomization and follow-up.
The patients who experienced major, minor, and periopera-
tive bleeding were allowed to proceed to randomization atThe Journal of Thoracic and Carthe investigator’s judgment; however, most patients who
had experienced major bleeding were not randomized.
One patient who experienced a minor stroke in the preran-
domization period was mistakenly randomized and was
immediately withdrawn from the study.
The results of the primary endpoint events are listed in
Table 2. Figure 3 provides primary endpoint life tables for
overall bleeding and TE, including their 5-year event-free
rates. The linearized event rates demonstrated that the test
group experienced a significant improvement in both major
and minor bleeding, with an overall 62% reduction in
bleeding events. The life tables confirmed this, depicting
a bleeding curve for the test group significantly below
that for the control group.
Both the linearized and life table analyses found no sig-
nificant difference in the rates of thrombotic events between
the 2 groups. The difference in bleeding events between the
2 groups was large enough to drive the comparison of com-
posite bleeding and TE rates between groups to statistical
significance (P¼ .046), in favor of the test group. No differ-
ences were seen in mortality between the 2 groups; the rates
of other valve-related events not shown in Table 2 were all
<1%/pt-yr and were similar between the 2 groups.
Before randomization, 4 patients had died within the first
30 days and 4 more between 30 and 90 days. The 4 early
deaths were from cardiogenic shock, multiorgan failure, bi-
ventricular failure, and atheroembolic shower leading to
renal failure; all occurred within 2 days of surgery. The 4
deaths occurring at 30 to 90 postoperative days were from
sudden death of unknown cause, prosthetic endocarditis, ce-
rebral hemorrhage, and arrhythmia.
After randomization, the incidence of sudden death was
the same in both groups (3 [0.44%/pt-yr]). One cardiac
death occurred in the control group due to chronic obstruc-
tive pulmonary disease and congestive heart failure. No
other late cardiac deaths occurred. Valve-related deaths
included cerebral bleeding in the control group and 1
ischemic stroke and 1 cerebral bleeding in the test group.
The remaining late deaths were determined by independent
adjudication to be noncardiac. In the control group, these
included 3 from cancer, 1 from multisystem organ failure,diovascular Surgery c Volume 147, Number 4 1205
FIGURE 2. Relationship between the international normalized ratio
(INR) at the event and the event rates. TE, Thromboembolism.
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D1 from pancreatitis, and 1 from sepsis. In the test group,
noncardiac deaths included 2 from cancer, 1 from cerebral
artery disease, 1 from chronic obstructive pulmonary dis-
ease with pulmonary embolism, and 1 from traumatic death.
A qualitative evaluation of reoperation and explants re-
vealed that the types and causes of the reoperations and ex-
plants were those generally expected after AVR and were
similar between the 2 groups. Before randomization, the
most common surgical procedure was re-exploration forTABLE 2. AVR high-risk postrandomization event comparisons
Primary event
Test group (pt-yr ¼ 675.2) Control gr
Patients (n) Rate (%/pt-yr) Patients (n)
Bleeding
Major 10 1.48 25
Hemorrhagic stroke 1 0.15 2
Death 1 0.15 1
Long-term* 0 0.00 1
Short-termy 0 0.00 0
Minor 8 1.18 25
Total 18 2.67 50
Ischemic stroke 5 0.74 5
Death 1 0.15 0
Long-term* 1 0.15 2
Short-termy 3 0.44 3
TIA 9 1.33 6
Neurologic event 14 2.07 11
Peripheral TE 4 0.59 1
All TE 18 2.67 12
Thrombosis 2 0.30 2
TE and thrombosis 20 2.96 14
Major event (major bleeding,
all TE, thrombosis)
30 4.44 39
All above events 38 5.63 64
Sudden death 3 0.44 3
Valve-related death (without
sudden)
2 0.30 1
Cardiac death 0 0.00 1
Noncardiac death 5 0.74 6
Total mortality 10 1.48 11
pt-yr, Patient-year; CI, confidence interval; NA, not applicable; TIA, transient ischemic att
1206 The Journal of Thoracic and Cardiovascular Surperioperative bleeding, which occurred 22 times (5.2% or
about one half of all perioperative bleeding events). New
pacemaker insertion within 14 days was the second most
common procedure and occurred in 19 patients (4.5%).
Other early procedures were for gastrointestinal bleeding,
prosthetic endocarditis, sternal rewiring, and an occult preg-
nancy; each occurred once. After randomization, valve-
related reoperations were related to prosthetic endocarditis
(1 control, explanted; 4 test, 3 explanted), paravalvular leak
(1 control, repaired; 1 test, explanted), thrombosis (1 con-
trol, explanted; 2 test, 1 explanted), peripheral thrombec-
tomy (1 control; 2 test), bleeding (1 control; 2 test), and
heart transplantation (1 test, explanted). Overall, the rate
of postrandomization reoperations was 0.66%/pt-yr for
the control group and 1.77%/pt-yr for the test group
(P ¼ .053), and the rate of explants was 0.26% in the con-
trol and 0.89% in the test groups (P ¼ .115). Types and
numbers of reoperations and explants are statistically
similar between groups.
TIA was defined as a neurologic deficit lasting 3 days.
Five TIAs occurred in the control group, with an average
duration of 1.6 days, and seven in the test group, averaging
1 day in duration. These were all short-duration blindness,
numbness, weakness, or tingling in patients whoseoup (pt-yr ¼ 755.7)
Rate ratio (test/control) 95% CI P valueRate (%/pt-yr)
3.31 0.45 0.21-0.94 .032
0.26 0.56 0.01-10.7 .630
0.13 1.15 0.01-87.8 .937
0.13 NA NA NA
0.00 NA NA NA
3.31 0.36 0.16-0.79 .011
6.62 0.40 0.24-0.69 <.001
0.66 1.12 0.32-3.87 .859
0.00 NA NA NA
0.26 0.56 0.01-10.7 .630
0.40 1.12 0.15-8.35 .891
0.79 1.68 0.60-4.72 .326
1.46 1.42 0.65-3.14 .380
0.13 4.48 0.50-40.06 .180
1.59 1.68 0.81-3.49 .164
0.26 1.12 0.16-7.95 .910
1.85 1.60 0.81-3.17 .178
5.16 0.86 0.54-1.40 .539
8.47 0.66 0.44-0.99 .046
0.40 1.12 0.23-5.55 .890
0.13 2.24 0.20-24.69 .511
0.13 NA NA NA
0.79 0.93 0.23-3.67 .908
1.46 1.02 0.43-2.40 .968
ack; TE, thromboembolism. *More than 3 days. yWithin 3 days or less.
gery c April 2014
FIGURE 3. Kaplan-Meier life tables with 5-year event-free rates. A, Kaplan-Meier plot of major or minor bleeding events. B, Kaplan-Meier plot of throm-
boembolism. SE, Standard error.
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scans showed no circulation abnormality or new cerebral
infarction. Five ischemic strokes each occurred in the con-
trol and test groups. Of these, 3 each in the control and test
groups had resolved within 3 days but the computed tomog-
raphy and magnetic resonance imaging results were posi-
tive. Two control patients and 1 test patient experienced a
permanent neurologic deficit, and 1 test patient died of
stroke on the second postoperative day. No significant dif-
ference was found in the incidence of neurologic events be-
tween the 2 groups as shown in Table 2.
A review of the PROACT database with>53,000 INR
measurements revealed that the level of anticoagulation at
the TE event was worthy of attention. TEs did not consis-
tently occur if the INR was below the target range in either
group. Overall, the percentage of TE events that occurred
with the patient within the INR target range was 67% (6
of 9) in the control group and 53% (8 of 15) in the test group
(P ¼ .806). In each group, 1 patient was greater than the
INR target range at the occurrence of the TE event. However,
22% (2 of 9) were at less than the target range in theThe Journal of Thoracic and Carcontrol group and 40% (6 of 15) were at less than the
INR target range in the test group (P ¼ .646) at TE. These
data suggest that an INR of 1.5 might be the bottom of the
appropriate range of anticoagulation for high-risk AVR
patients.
Valve thrombosis was qualitatively different from TE in
that all 4 valve thrombosis events occurred in patients
who had stopped taking warfarin against medical advice.
These cases were managed by valve explantation (1 control
and 1 test), 1 thrombectomy, and 1 spontaneous resolution
with the re-administration of warfarin. All 4 patients
recovered.
Of the primary endpoint events, 35 were major bleeding
events, 34 minor, 10 strokes, and 15 were TIAs. Major
bleeding events were further classified into 5 cerebral
events, 27 gastrointestinal, 3 hematomas, and 2 nosebleeds.
All these patients, except for those with cerebral bleeding
events, had recovered after a median of 8 days. Cerebral
bleeding events resulted in 2 deaths and 1 permanent deficit.
The patients who experienced TIAs all recovered without
treatment within<3 days. Nonhemorrhagic strokes resulteddiovascular Surgery c Volume 147, Number 4 1207
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ered fully within<3 days. These were only classed as cere-
brovascular accidents because the computed tomography or
magnetic resonance imaging scans found a clot. The clin-
ical implications of hemorrhagic cerebral events were
much more severe than the consequences of nonhemorrha-
gic strokes in this limb of the PROACT study. A summary of
all cerebrovascular events by group has been included in
Table 2.
The distribution of valve sizes in the high risk limb of the
PROACT trial mirrored common practice in mechanical
aortic valve replacement, with 45 of 425 valves size 19
mm, 122, size 21 mm, 145, size 23 mm, 61, size 25 mm,
and 39 valves size 27/29 mm. No significant differences
were found in the relative risk of TE or hemorrhagic events
between the test and control groups across the different
valve sizes.
DISCUSSION
In 1995, Cannegieter and colleagues8 published an in-
depth analysis of anticoagulation and adverse events in
early model mechanical valves. The development of a
normalized method of evaluating the anticoagulant status
through the INR for prothrombin time allowed the compar-
ison of event rates across a large number of patients accord-
ing to their anticoagulation level. Cannegieter and
colleagues8 defined an optimum range for INR to minimize
thrombotic and hemorrhagic complications. Thrombotic
events occurred more frequently as the INR decreases and
hemorrhagic events have been more common as the INR in-
creases; thus, the zone at which the 2 event curves intersect
defines the optimum therapeutic INR. The recommenda-
tions for the proper level of anticoagulation for heart valves
of various types and under various circumstances have
ranged over the years from 2.0 to 4.5. At present, the
accepted range for a bileaflet mechanical valve in the aortic
position is 2.0 to 3.0 and in the mitral position is 2.5 to
3.5.4,5
Horstkotte and colleagues9 and Cannegieter and col-
leagues8 recognized that the bleeding event curve is essen-
tially independent of the valve type, being more directly
related to patient factors and the level of anticoagulation,
and can be considered a constant curve. The thrombotic
event curve, however, is the result of a more complicated
mix of factors, including patient factors, valve factors,
and the anticoagulation level. It is reasonable to speculate
that if every valve were examined by these methods, a fam-
ily of curves would result. If the patient factors were held
constant by careful patient selection, the resulting family
of curves would represent the relative thrombogenicity of
each valve, with the more resistant valves toward the left.
The optimum INR range for the more thromboresistant
valve would be lower and the end result would be fewer
complications (combined TE and bleeding events) for1208 The Journal of Thoracic and Cardiovascular Surpatients with that valve. Butchart,10 in a review of embolism
in prosthetic heart valves, concluded that valves vary in sus-
ceptibility to thrombosis owing to subtle design differences,
that the optimal INR range is often uncertain, and that addi-
tional research is needed.
Many studies of various mechanical valves have exam-
ined low-intensity warfarin therapy, warfarin plus aspirin,
aspirin alone, and, even, no anticoagulation. These studies
have had mixed results. Horstkotte and colleagues9 sug-
gested that INR levels of 3.0 to 4.5 were too high for the
St Jude valve; however, a prospective trial is needed to
determine the optimal level. Cannegieter and colleagues,8
in the first detailed study of optimum anticoagulation, sug-
gested a target INR of 3.0 to 4.5. More recently, Torella and
colleagues11 reported a successful randomized trial in low-
risk mechanical AVR patients in whom the INR was main-
tained at 1.5 to 2.5. Bleeding was significantly reduced in
the test group and the TE rates were noninferior.11 Others
have suggested lower INR targets in the range of 2.0 to
3.0.9,12,13 These studies resulted in the present
recommendations of American College of Clinical
Pharmacy5 and American Heart Association/American
College of Cardiology.4
Turpie and colleagues14 and other groups15,16 have
reported the benefit of adding aspirin or dipyridamole to
warfarin therapy. Others have suggested a possible
increase in the risk of bleeding with the addition of
aspirin.17 A meta-analysis18 supported the addition of
low-dose aspirin or dipyridamole to warfarin for patients
with mechanical cardiac valve prostheses.
Another strategy to reduce the TE and bleeding events
associated with warfarin therapy has been to more closely
manage anticoagulation therapy with frequent clinic or
home monitoring of INR. These studies have uniformly
shown better clinical outcomes with better control.19-21
The low overall rates of adverse hemorrhagic and
thromboembolic events observed in the PROACT trial
might have been due, in part, to the uniform use of home
INR monitoring and the high degree of compliance
among the enrolled patients.
Several investigations have explored the thrombogenicity
of the On-X bileaflet mechanical valve. In 1996, the first
clinical trial of the On-X valve to establish its safety and
effectiveness began in Europe and included 184 AVR pa-
tients. The final report of the study was completed in
2004 with a minimum of 5 years of follow-up per patient.
This report was published by Palatianos and colleagues,22
with a late TE rate of 0.88%/pt-yr and bleeding rate
of 0.77%/pt-yr. Chambers and colleagues24 published a
12-year experience with a 0.6%/pt-yr TE rate for AVR
patients combined with a 0.4%/pt-yr major bleeding rate.
The patients in the present trial were monitored clinically
with an INR target of 2 to 3. In an ongoing clinical trial
in South Africa,23 104 On-X AVR valves were implanted,gery c April 2014
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these patients were not receiving anticoagulation therapy
because of the social conditions in South Africa, no AVR
thromboses were reported in their study.23 The late TE
rate was 1.1%/pt-yr, and the bleeding rate was 0.6%/pt-
yr. Low TE rates with the On-X valve might be attributable
to several design features, including its manufacture from
pure pyrolytic carbon,25 a flared inlet, increased height to
cylinder ratio, 180 leaflet opening, and increased
‘‘washing’’ of potentially thrombogenic hinge points.
A total of 14 patients (3.7% of the total) had preoperative
atrial fibrillation. Three of these were randomized to the test
group and were treated with an INR of 1.5 to 2.0 and aspirin
81 mg/d. This FDA-sanctioned protocol treated some of
these patients with slightly less aggressive anticoagulation
than present guidelines would recommend. However, no
TE or hemorrhagic events occurred in any of these 14
patients.
In the present PROACT study, high-risk AVR patients ran-
domized after 3 postoperative months of standard anticoagu-
lation to receive reduced warfarin therapy (INR, 1.5-2.0)
with aspirin 81 mg/d experienced a lower incidence of
bleeding complications and a similar incidence of thrombotic
complications compared with those who continued standard
anticoagulation. TE events were more common when the
INR had decreased to<1.5. Bleeding events weremore com-
mon in the test and control groups both when the INR had
increased to greater than the target range. Compliance with
home INRmonitoring was associated with tight INR control
and fewer TE and bleeding complications.
Study Limitations
The PROACT study had numerous limitations. Perhaps,
most importantly, all patients reported in the present study
underwent AVR with a single, approved, bileaflet mechan-
ical valve prosthesis. The results from the present trial
should not be extrapolated to other prostheses, mechanical
mitral valve replacements, or patients undergoing double
AVR/mitral valve replacement. The present standard of
care for all mechanical AVR patients outside the PROACT
study remains conventional anticoagulation, as indicated by
the American Heart Association/American College of Car-
diology guidelines.4
Although the high-risk AVR limb of the PROACT
demonstrated that a target INR range of 1.5 to 2.0 combined
with low-dose aspirin therapy can be safe and efficacious,
this does not imply that an INR value at either end of the
range is of equal benefit. TE events were more common
in high-risk AVR patients when the INR decreased to<1.5.
The sample size of PROACT was not designed to deter-
mine whether less aggressive anticoagulation therapy is
safe for different sizes of On-X AVR prostheses, although
the data obtained did not indicate a predisposition toward
more adverse events with larger or smaller valve sizes.The Journal of Thoracic and CarCONCLUSIONS
INR can be safely maintained at 1.5 to 2.0 in high-risk
AVR patients after implantation of this approved bileaflet
mechanical prosthesis. Combined with low-dose aspirin,
this therapy resulted in a significantly lower risk of bleeding
than the customary INR range of 2.0 to 3.0, without a signif-
icant increase in TE events. To maximize the safety and
effectiveness of this therapeutic change in high-risk AVR
recipients of On-X valves, the INR should be assiduously
kept>1.5.References
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Dr A. Peter Kappetein (Rotterdam, The Netherlands). The
conflict of interest that I have to report is that I am a member of
the steering committee of the RE-ALIGN (The Randomized,
Phase II Study to Evaluate the Safety and Pharmacokinetics
of Oral Dabigatran Etexilate in Patients After Heart Valve
Replacement) trial, which tested dabigatran in patients with
mechanical heart valves.
Dear Dr Puskas, thank you very much for your excellent
presentation and thank you for sending the report in advance of
this meeting. Treatment with oral anticoagulant drugs is effective
in the prevention of TE but inevitably increases the risk of bleeding
events. Although low-dose anticoagulation leads to more
thromboembolic events, a dosage that is too high can lead to
hemorrhage. Anticoagulation monitoring and adjustment of the
dosage is therefore steering safely between Scylla and Charybdis.
The trial that you just presented is a noninferiority trial.
The difficulty with this type of study design is choosing the
right noninferiority margin, the so-called delta. Because no
meaningful data are available comparing warfarin to placebo
with prosthetic heart valves, there is no ability to construct
additional noninferiority boundaries.
Your sample size estimation was based on a 1-sided proportion
test with type 1 error of 0.05 and a power of 80% to test this
noninferiority hypothesis with an absolute noninferiority margin
of 1.5%. The event rates on which you based your sample size
calculation were not mentioned in the report; however, usually
the TE rates will be as high as 3% to 4% annually among
mechanical valve patients, and valve thrombosis can occur in
0.5% of mechanical valve patients annually. In contemporary
practice, the risk of significant hemorrhage has been reported at
2% to 3%. The number of patients in your trial was extremely1210 The Journal of Thoracic and Cardiovascular Surlow, only 375 divided into 2 arms. The comment and question
that I have are the following.
When you lower the anticoagulation treatment, you will always
lower the bleeding events, no doubt about this, although the valve
thrombosis and thromboembolic events could increase. However,
you cannot put 2 events in a composite endpoint of a noninferiority
trial if they do not point in the same direction. It might well be that
bleeding events will decrease more than thromboembolic events
will increase. In this study, you mixed the efficacy endpoints
with the safety endpoints.
During the past couple of years, new anticoagulant drugs have
been tested against warfarin in patients with atrial fibrillation.
The thromboembolic events were even greater than those in the
patients with mechanical heart valves, and these studies more or
less used the same noninferiority margin that you used in your
study. However, these studies included many more patients:
ARISTOTLE (Apixaban vs Warfarin in patients with Atrial
Fibrillation), 18,000 patients; ROCKET (Rivaroxaban Once Daily
Oral Direct Factor Xa Inhibition Compared With Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation), 14,000 patients; and RELY (Randomized Evaluation
of Long-Term Anticoagulation Therapy), 15,000 patients. You
could have saved those companies a lot of money with your study
design.
My question is, should we regard this trial as a pilot study and
should we not base the sample size only on the efficacy endpoint,
being thromboembolic events, and in that case, should we design a
new trial and increase the sample size to around 8000 patients and
try to find the money for the trial somewhere? Is it not potentially
dangerous if we do not know what the increase is of valve
thrombosis and follow your conclusions?
Then another question. Should a third arm of the new trial include
one of the new anticoagulant drugs?What do you think is the reason
that dabigatran worked in the patients with atrial fibrillation but did
not work in the patients with mechanical heart valves?
Thank you very much.
Dr Puskas. Thank you, Pieter. I share your concern about a
noninferiority design for our trial. It was certainly a topic of
much discussion with the FDA 8 years ago when this trial
was designed and approved by the FDA. As you commented,
thrombotic events and hemorrhagic events were not moving in
the same direction, and this is just as we would expect. I showed
a slide that recapitulates old studies that showed that thrombotic
events move in one direction and bleeding events in the other.
What we are really looking for is to determine a ‘‘sweet spot’’
where those 2 curves intersect. Although it is theoretically or
intellectually correct to say that thrombosis is the efficacy issue
and hemorrhage the safety issue, we were obliged to combine
those, for 2 reasons. First, the practical reason, no company will
sponsor an 8000-patient, randomized trial; and second, the clinical
reason, this was in fact a tradeoff in the minds of the patients
and clinicians. So, it is a relevant clinical endpoint, this unholy
composite, if you will, of thrombosis and hemorrhage.
The factors that affect bleeding are probably valve independent
for the most part. They relate to the patient and the anticoagulant
administered. The factors that affect thromboembolism or throm-
bosis include the above and patient factors and factors related to
the therapy administered; however, they also involve, importantly,gery c April 2014
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investigational device exemption is trying to study the valve and
whether this particular valve has a different ‘‘sweet spot’’ in terms
of the risk of bleeding and thrombosis relative to other valves.
Now, I do not work for the company; I have no financial
relationship with the company. I am impressed by the design of
the valve from an engineering point of view and from a materials
point of view. The present study really was to determine whether
that difference in design will move the TE curve along the bleeding
curve such that the ‘‘sweet spot’’ would be lower and more
attractive to patients and clinicians. I think that is an appropriate
answer to your first question.
In terms of your second question, why did dabigatran not work; I
am amazed it did not work. One of the elements of that trial was that
double valves were allowed. It was sort of an ‘‘all-comers’’ type of
trial. I wonder if that had been held strictly to isolated AVR or
isolated mitral valve replacement, whether you might have had a
different result. However, direct thrombin inhibitors are relatively
new, and we do not understand them as well as we understand
warfarin, which has been around for 40 years. Another possible
explanationmight relate to the relatively short half-life of dabigatran
and that the dabigatran trial did not include aspirin administration. A
patient in the dabigatran trial who skipped 1 or 2 doses of dabigatran
with, for example, a double mechanical valve replacement, is
immediately at high risk of a thrombotic event. In contrast, a patient
who skips 1 dose ofwarfarinwhile also taking aspirin is probably at a
lesser immediate risk of thromboembolic events. The increased
hemorrhagic complications seen in the dabigatran trial might have
been related to the rather high dose of the drug given in that trial.
However, these explanations are speculative.
Dr Hartzell V. Schaff (Rochester, Minn). In one of the slides I
think I saw that you had 6 reoperations in 1 group.What were those
for?
Dr Puskas. Early reoperation for bleeding was the most
common perioperative event, and those were typically before
randomization.
Dr Michael A. Acker (Philadelphia, Pa). One of the key
elements to your design was point of care testing at home for
both groups. That is not universally done; in fact, I would say
across the United States, that is unusual. Do you think these results
would hold up, given a standard practice of managing it, because
that type of tight control is probably not the real world.
Dr Puskas. It (point-of-care home INR testing) is not the real
world in America now. It is the real world in Scandinavia andThe Journal of Thoracic and Carsome other regions. So, I think your comment is absolutely well
taken, Mike.
We found in careful analysis of the 53,000 INR endpoints that
we have and correlating those with adverse events that the
variability in INR is very important in affecting adverse events,
both bleeding and clotting, and it seems to be more impactful
than the actual mean INR. Whether you are in the test group,
with an INR of 1.5 to 2, or in the control group, INR 2 to 3, it would
seem to matter more whether you are good about doing your
testing and controlling your INR in your range than which range
you are in. Bleeding events can occur after a relatively brief period
high outside the range; hemorrhagic events are particularly
sensitive to (poor) INR control.
I think that we in America need to catch up with what should be
considered the standard of care in other parts of the world. Home
INR monitoring is available, it is not high tech, and it is much
easier for patients. To be perfectly blunt, there is really no excuse
for us not using it uniformly in America.
Dr Acker. There is a reimbursement issue, as you know.
Dr Puskas. It, quite frankly, is a conflict of interest for local
care providers and their patients’ well-being. A small revenue
stream occurs to cardiology offices and primary care doctors
running warfarin clinics, and that is keeping us in the system
that we have now rather than home INRmonitoring through larger,
centralized warfarin clinics. The coordination of home INR
monitoring and clinical care in the present trial is far better than
what I have provided to my own patients in the past. However,
with the knowledge we have gained from the PROACT trial, we
are strongly encouraging home INR monitoring for all patients
who are treated with warfarin.
DrMohamed Emara (Cairo, Egypt).Did you face the problem
that you cannot reach even this target of low INR with a large dose
of warfarin, and what type of warfarin do you use, hydrophobic or
hydrophilic?We have this problem in Egypt. Sometimes, we reach
to 11 mg and we do not reach>1.2. What is your comment about
that?
Dr Puskas. There are a small number of patients who are
relatively warfarin resistant and require large doses, but we
have not had to exclude anybody from the trial because of
an inability to anticoagulate them. The patients were encouraged
to use brand name warfarin, but not all did, and generic
warfarin was used by some patients. Thus, I cannot tell you that
everybody received exactly the same kind of warfarin. That was
not feasible.diovascular Surgery c Volume 147, Number 4 1211
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APPENDIX E2. Consolidated Standards of Reporting Trials (CONSORT) 2010 flow diagram. Reprinted, with permission, from Schulz KF, Altman DG,
Moher D, for the CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Ann Intern Med.
2010;152:726-32.
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